Manisha Vohra, Mohammad Amir, Ian Osoro, Amit Sharma, Ranjeet Kumar
{"title":"Impact of vericiguat on heart failure with reduced ejection fraction: a review","authors":"Manisha Vohra, Mohammad Amir, Ian Osoro, Amit Sharma, Ranjeet Kumar","doi":"10.1016/j.glohj.2023.07.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Heart failure is a major public health issue with a prevalence of about 26 million people worldwide. Reduced nitric oxide availability, lower soluble guanylate cyclase (sGC) activity, and decreased cyclic guanosine monophosphate (cGMP) production are the causes of HF's development. Vericiguat prescribed under the brand name Verquvo was approved by U.S. Food and Drug Administration (FDA) in January 2021. It is a novel agent and the first sGC stimulator which helps to treat patients suffering from heart failure with reduced ejection fraction (HFrEF).</p></div><div><h3>Objective</h3><p>The mechanism of action (cGMP pathway) of vericiguat, its clinical trials, its use in the treatment of heart failure, and its possible future aspects in therapeutic recommendations are all covered in this review. It will also raise awareness amongst healthcare professionals about the pharmacokinetic and pharmacodynamic parameters, dosing, administration, and drug-related problems of this new drug.</p></div><div><h3>Methods</h3><p>Various databases for drug review were used in this review like PubMed, Medline, Google scholar, Drug bank, U.S. FDA, Medscape, and European society of cardiology guidelines. A total of 58 articles were screened out of which 39 articles were included in this review.</p></div><div><h3>Results</h3><p>This review discusses vericiguat's mechanism of action (cGMP pathway), clinical studies, application in the treatment of heart failure, and potential future considerations in therapeutic recommendations. It will also educate healthcare professionals about the new drug's pharmacokinetics and pharmacodynamics, dose, administration, and drug-related problems.</p></div><div><h3>Conclusion</h3><p>After hospitalization for HFrEF, the 5-year survival rate is just 25%, and disease morbidity and death are still significant. As adjunctive therapy for individuals with heart failure and a low ejection fraction, vericiguat has a moderate level of effectiveness. Vericiguat's efficacy as an adjunct therapy to different drugs used to cure HF has to be further investigated. Vericiguat's safety and dosage in patients who have severe renal or hepatic illness need to be studied further.</p></div>","PeriodicalId":73164,"journal":{"name":"Global health journal (Amsterdam, Netherlands)","volume":"7 3","pages":"Pages 123-129"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global health journal (Amsterdam, Netherlands)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2414644723000696","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Introduction
Heart failure is a major public health issue with a prevalence of about 26 million people worldwide. Reduced nitric oxide availability, lower soluble guanylate cyclase (sGC) activity, and decreased cyclic guanosine monophosphate (cGMP) production are the causes of HF's development. Vericiguat prescribed under the brand name Verquvo was approved by U.S. Food and Drug Administration (FDA) in January 2021. It is a novel agent and the first sGC stimulator which helps to treat patients suffering from heart failure with reduced ejection fraction (HFrEF).
Objective
The mechanism of action (cGMP pathway) of vericiguat, its clinical trials, its use in the treatment of heart failure, and its possible future aspects in therapeutic recommendations are all covered in this review. It will also raise awareness amongst healthcare professionals about the pharmacokinetic and pharmacodynamic parameters, dosing, administration, and drug-related problems of this new drug.
Methods
Various databases for drug review were used in this review like PubMed, Medline, Google scholar, Drug bank, U.S. FDA, Medscape, and European society of cardiology guidelines. A total of 58 articles were screened out of which 39 articles were included in this review.
Results
This review discusses vericiguat's mechanism of action (cGMP pathway), clinical studies, application in the treatment of heart failure, and potential future considerations in therapeutic recommendations. It will also educate healthcare professionals about the new drug's pharmacokinetics and pharmacodynamics, dose, administration, and drug-related problems.
Conclusion
After hospitalization for HFrEF, the 5-year survival rate is just 25%, and disease morbidity and death are still significant. As adjunctive therapy for individuals with heart failure and a low ejection fraction, vericiguat has a moderate level of effectiveness. Vericiguat's efficacy as an adjunct therapy to different drugs used to cure HF has to be further investigated. Vericiguat's safety and dosage in patients who have severe renal or hepatic illness need to be studied further.
心力衰竭是一个重大的公共卫生问题,全世界约有2600万人患有心力衰竭。一氧化氮可用性降低,可溶性鸟苷酸环化酶(sGC)活性降低,环鸟苷单磷酸(cGMP)生成减少是HF发展的原因。Vericiguat品牌名为Verquvo,于2021年1月获得美国食品和药物管理局(FDA)的批准。它是一种新型药物和第一种sGC刺激剂,有助于治疗心力衰竭伴射血分数降低(HFrEF)的患者。目的综述vericiguat的作用机制(cGMP途径)、临床试验、在心力衰竭治疗中的应用以及今后在治疗推荐中的应用前景。它还将提高卫生保健专业人员对这种新药的药代动力学和药效学参数、剂量、给药和药物相关问题的认识。方法采用PubMed、Medline、Google scholar、drug bank、U.S. FDA、Medscape、European society of cardiology guidelines等药物审评数据库。共筛选了58篇文献,其中39篇纳入本综述。结果本文综述了vericiguat的作用机制(cGMP途径)、临床研究、在心力衰竭治疗中的应用,以及未来可能考虑的治疗建议。它还将教育医疗保健专业人员关于新药的药代动力学和药效学、剂量、管理和药物相关问题。结论HFrEF住院后5年生存率仅为25%,疾病发病率和死亡率仍显著。作为心力衰竭和低射血分数个体的辅助治疗,vericiguat具有中等水平的有效性。Vericiguat作为治疗HF的不同药物的辅助疗法的疗效有待进一步研究。Vericiguat在严重肾脏或肝脏疾病患者中的安全性和剂量需要进一步研究。